|
1
|
Bastola P, Stratton Y, Kellner E,
Mikhaylova O, Yi Y, Sartor MA, Medvedovic M, Biesiada J, Meller J
and Czyzyk-Krzeska MF: Folliculin contributes to VHL tumor
suppressing activity in renal cancer through regulation of
autophagy. PLoS One. 8:e700302013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
4
|
Kovacs G, Akhtar M, Beckwith BJ, Bugert P,
Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros
LJ, et al: The Heidelberg classification of renal cell tumours. J
Pathol. 183:131–133. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramakrishnan S, Ellis L and Pili R:
Histone modifications: Implications in renal cell carcinoma.
Epigenomics. 5:453–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim HL, Seligson D, Liu X, Janzen N, Bui
MH, Yu H, Shi T, Figlin RA, Horvath S and Belldegrun AS: Using
protein expressions to predict survival in clear cell renal
carcinoma. Clin Cancer Res. 10:5464–5471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu
YH, Sung JS, Cha TL and Sun GH: Tumor-derived tumor necrosis
factor-alpha promotes progression and epithelial-mesenchymal
transition in renal cell carcinoma cells. Cancer Sci. 99:905–913.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Solomon JP, Page LJ, Balch WE and Kelly
JW: Gelsolin amyloidosis: Genetics biochemistry pathology and
possible strategies for therapeutic intervention. Crit Rev Biochem
Mol Biol. 47:282–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li GH, Arora PD, Chen Y, McCulloch CA and
Liu P: Multifunctional roles of gelsolin in health and diseases.
Med Res Rev. 32:999–1025. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baig RM, Mahjabeen I, Sabir M, Masood N,
Ali K, Malik FA and Kayani MA: Mutational spectrum of gelsolin and
its down regulation is associated with breast cancer. Dis Markers.
34:71–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Visapää H, Bui M, Huang Y, Seligson D,
Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S and
Palotie A: Correlation of Ki-67 and gelsolin expression to clinical
outcome in renal clear cell carcinoma. Urology. 61:845–850. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Finley DS, Pantuck AJ and Belldegrun AS:
Tumor biology and prognostic factors in renal cell carcinoma.
Oncologist. 16(Suppl 2): S4–S13. 2011. View Article : Google Scholar
|
|
14
|
Nag S, Larsson M, Robinson RC and Burtnick
LD: Gelsolin: The tail of a molecular gymnast. Cytoskeleton
(Hoboken). 70:360–384. 2013. View
Article : Google Scholar
|
|
15
|
Arora PD, Wang Y, Bresnick A, Dawson J,
Janmey PA and McCulloch CA: Collagen remodeling by phagocytosis is
determined by collagen substrate topology and calcium-dependent
interactions of gelsolin with nonmuscle myosin IIA in cell
adhesions. Mol Biol Cell. 24:734–747. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ke H, Zhang JY, Akiyama SK and French JE:
BCL2 interaction with actin in vitro may inhibit cell motility by
enhancing actin polymerization. Cell Adh Migr. 5:6–10. 2011.
View Article : Google Scholar :
|
|
17
|
Zhuo J, Tan EH, Yan B, Tochhawng L,
Jayapal M, Koh S, Tay HK, Maciver SK, Hooi SC, Salto-Tellez M, et
al: Gelsolin induces colorectal tumor cell invasion via modulation
of the urokinase-type plasminogen activator cascade. PloS One.
7:e435942012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu WY, Hunag YY, Liu XG, He JY, Chen DD,
Zeng F, Zhou JH and Zhang YK: Prognostic evaluation of CapG
gelsolin P-gp GSTP1 and Topo-II proteins in non-small cell lung
cancer. Anat Rec (Hoboken). 295:208–214. 2012. View Article : Google Scholar
|
|
19
|
De Corte V, Bruyneel E, Boucherie C,
Mareel M, Vandekerckhove J and Gettemans J: Gelsolin-induced
epithelial cell invasion is dependent on ras-rac signaling. EMBO J.
21:6781–6790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao CJ, Wu TI, Huang YH, Chang TC, Wang
CS, Tsai MM, Hsu CY, Tsai MH, Lai CH and Lin KH: Overexpression of
gelsolin in human cervical carcinoma and its clinicopathological
significance. Gynecol Oncol. 120:135–144. 2011. View Article : Google Scholar
|
|
21
|
Zhan L, Zhang H, Zhang Q, Woods CG, Chen
Y, Xue P, Dong J, Tokar EJ, Xu Y, Hou Y, et al: Regulatory role of
KEAP1 and NRF2 in PPARγ expression and chemoresistance in human
non-small-cell lung carcinoma cells. Free Radic Biol Med.
53:758–768. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park SM, Hwang IK, Kim SY, Lee SJ, Park KS
and Lee ST: Characterization of plasma gelsolin as a substrate for
matrix metalloproteinases. Proteomics. 6:1192–1199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anbiaee R, Mojir Sheibani K, Torbati P and
Jaam H: Abnormal expression of e-cadherin in gastric adenocarcinoma
and its correlation with tumor histopathology and helicobacter
pylori infection. Iran Red Crescent Med J. 15:218–222. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rao J, Seligson D, Visapaa H, Horvath S,
Eeva M, Michel K, Pantuck A, Belldegrun A and Palotie A: Tissue
microarray analysis of cytoskeletal actin-associated biomarkers
gelsolin and E-cadherin in urothelial carcinoma. Cancer.
95:1247–1257. 2002. View Article : Google Scholar : PubMed/NCBI
|
